Carregant...
Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
INTRODUCTION: Ovarian cancer has only a 17% 5‐year survival rate in patients diagnosed with late stage disease. Tumor‐associated glycoprotein‐72 (TAG72), expressed in 88% of all stages of ovarian cancer, is an excellent candidate for antibody‐targeted therapy, as it is not expressed in normal human...
Guardat en:
| Publicat a: | Cancer Med |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7333846/ https://ncbi.nlm.nih.gov/pubmed/32368864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3078 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|